News and Updates

Nitinotes launches the EASE™ clinical trial at Italy’s Gemelli Hospital, advancing minimally invasive endoscopic suturing for obesity treatment.

Pulse Biosciences completes enrollment for the PRECISE-BTN study, evaluating the Vybrance system for minimally invasive treatment of benign thyroid nodules.

New data confirms long-term efficacy for COMP360 psilocybin, but Compass Pathways now faces the significant challenge of scaling psychedelic therapy safely.

Adia Med has submitted its fifth 2026 clinical protocol to the IRB, testing a breakthrough one-time systemic treatment for osteoarthritis patients.

Arrowhead Pharmaceuticals reports positive data for ARO-APOC3, a pioneering RNAi therapy targeting mixed hyperlipidemia to improve cardiovascular patient care.

Boehringer Ingelheim updates the EASi-KIDNEY trial on empagliflozin’s role in treating chronic kidney disease and preventing renal failure.

The FDA has released new guidelines for psychedelic drug trials. Learn how these regulatory standards will shape the future of mental health treatment.

New trial data shows ivonescimab outperforms pembrolizumab in treating PD-L1-positive NSCLC, marking a major advancement in lung cancer immunotherapy.

Clinical trial start-ups are stalling due to IRB submission errors. Discover why misreading regulatory pathways is causing delays and how to fix them.

Definium’s DT120 ODT hits primary endpoints in Phase 3 GAD trials, showing promise as a fast-acting, easy-to-use treatment for generalized anxiety.